We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ALX Oncology Holdings Inc | NASDAQ:ALXO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.26 | -7.58% | 15.36 | 7.62 | 17.50 | 17.13 | 15.2144 | 16.92 | 1,284,838 | 05:00:03 |
From May 2021 to May 2024
By Stephen Nakrosis
Clinical-stage immuno-oncology company ALX Oncology Holdings Inc. on Thursday said it received an orphan drug designation for evorpacept from the U.S. Food and Drug Administration.
ALX Oncology said it received the designation for evorpacept to treat patients with gastric cancer and gastroesophageal junction cancer.
The FDA grants orphan drug status to treatments for rare diseases and the designation qualifies the sponsor of the drug for various development incentives, including tax credits for qualified clinical testing.
Sophia Randolph, the company's chief medical officer, said, "Receiving orphan drug designation from the FDA is an important regulatory milestone for ALX Oncology and reinforces the FDA's recognition of evorpacept's potential to improve clinical outcomes in patients with GC."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 27, 2022 18:28 ET (23:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year ALX Oncology Chart |
1 Month ALX Oncology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
